Labcorp Holdings received
positive analyst ratings and announced their
first quarter financial results on April 30, 2026. The average rating by brokerages was a 'moderate buy'. They appointed
Victor Bulto to their Board of Directors and secured a
$750 million term loan. Labcorp also planned a quarterly dividend of $0.72 while expanding their testing initiatives and stock. However, Wall Street Zen downgraded their rating to 'hold'. They also announced an ambitious revenue growth by FY26 along with a bullish earnings recovery narrative. Labcorp's alliance with Illumina placed a focus on
precision oncology. The company also completed acquisition of select assets of BioReference Health.
More recently, Labcorp has launched AI tool for lab test selection
Test Finder and taken its
digital pathology nationwide. They also stuck a $195 million deal with Community Health Systems and purchased analytical testing services business in an $8.5 million deal. Despite this strong performance, their Q4 results were adversely impacted due to investor concerns.
Laboratory Corporation of America Holdings LH News Analytics from Wed, 05 Nov 2014 08:00:00 GMT to Sat, 11 Apr 2026 00:24:00 GMT -
Rating 7
- Innovation 8
- Information 8
- Rumor 5
